ES2685503T3 - Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos - Google Patents

Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos Download PDF

Info

Publication number
ES2685503T3
ES2685503T3 ES09764426T ES09764426T ES2685503T3 ES 2685503 T3 ES2685503 T3 ES 2685503T3 ES 09764426 T ES09764426 T ES 09764426T ES 09764426 T ES09764426 T ES 09764426T ES 2685503 T3 ES2685503 T3 ES 2685503T3
Authority
ES
Spain
Prior art keywords
vwf
adamts13
von willebrand
cleavage fragments
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09764426T
Other languages
English (en)
Inventor
Katalin Varadi
Hanspeter Rottensteiner
Peter Turecek
Hans-Peter Schwarz
Jutta Schreiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of ES2685503T3 publication Critical patent/ES2685503T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método para analizar la eficacia de un factor de von Willebrand (FvW) utilizado en el tratamiento de la enfermedad de von Willebrand (EvW) en un individuo, que comprende medir fragmentos de división de FvW en una muestra de sangre del individuo antes y después del tratamiento, en el que un aumento de los fragmentos de división de FvW después del tratamiento indica que una desintegrina y metaloproteinasa con un motivo de trombospondina de tipo 1, miembro 13 (ADAMTS13) endógena en el individuo está dividiendo el FvW, y en el que una disminución o una ausencia de fragmentos de división de FvW después del tratamiento indica que la ADAMTS13 endógena en el sujeto no está dividiendo el FvW, y en el que los fragmentos de división de FvW son generados por la actividad de la ADAMTS13, y en el que la división de FvW se lleva a cabo bajo tensión de cizalladura.
ES09764426T 2008-12-05 2009-12-03 Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos Active ES2685503T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12020208P 2008-12-05 2008-12-05
PCT/US2009/066588 WO2010065742A1 (en) 2008-12-05 2009-12-03 Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof

Publications (1)

Publication Number Publication Date
ES2685503T3 true ES2685503T3 (es) 2018-10-09

Family

ID=41682841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09764426T Active ES2685503T3 (es) 2008-12-05 2009-12-03 Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos

Country Status (9)

Country Link
US (6) US8415114B2 (es)
EP (2) EP3388529A1 (es)
JP (4) JP6111016B2 (es)
KR (1) KR101670103B1 (es)
AU (1) AU2009322367B2 (es)
CA (2) CA3098952A1 (es)
ES (1) ES2685503T3 (es)
PL (1) PL2358895T3 (es)
WO (1) WO2010065742A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685503T3 (es) * 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
CA2757585C (en) * 2010-11-17 2022-07-19 Puget Sound Blood Center Enhanced cleavage of von willebrand factor by adamts13
US11191818B2 (en) 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JP2019532649A (ja) 2016-10-11 2019-11-14 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ａｄａｍｔｓ１３酵素活性を決定するための方法およびシステム
JP7120558B2 (ja) * 2017-09-27 2022-08-17 国立大学法人東北大学 せん断応力負荷時のフォンウィルブランド因子高分子マルチマーの保持率のインビトロ測定法
JP7359775B2 (ja) * 2018-09-14 2023-10-11 テルモ株式会社 循環器障害または血栓形成の進行またはそのリスクの予測
US12128090B2 (en) * 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
JP2022536633A (ja) * 2019-06-07 2022-08-18 武田薬品工業株式会社 鎌状赤血球症の治療のための組換えａｄａｍｔｓ１３の使用
EP4652193A1 (en) * 2023-01-18 2025-11-26 Enzyre B.V. Luminescent detection of adamts13

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
DE20213920U1 (de) 2002-07-03 2003-01-16 Böhm, Martina, 60439 Frankfurt Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
CA2499926C (en) * 2002-09-25 2013-06-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Antibody against von willebrand factor cleaving enzyme and assay system using the same
WO2004035778A1 (ja) * 2002-10-18 2004-04-29 Japan As Represented By The President Of National Cardiovascular Center フォンビルブランド因子切断酵素の特異的基質および活性測定法
US7780831B2 (en) * 2003-07-07 2010-08-24 The University Of North Carolina At Chapel Hill Assays for detection of von willebrand factor (vWF) multimers and for degradation of vWF by agents such as ADAMTS13 and related methods
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
AU2006213411B2 (en) * 2005-02-14 2010-09-23 Alfresa Pharma Corporation Antibody for assay of ADAMTS13 activity and method of activity assay
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP2007024839A (ja) 2005-07-21 2007-02-01 Sekisui Chem Co Ltd 検体採取容器
CA2641189A1 (en) 2006-01-31 2007-08-09 Mitsubishi Kagaku Iatron, Inc. Method for determination of condition of disseminated intravascular coagulation syndrome
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
AU2008259839A1 (en) * 2007-05-31 2008-12-11 The Children's Hospital Of Philadelphia Compositions and methods for modulation of ADAMTS13 activity
CA2741634A1 (en) * 2008-10-27 2010-06-03 Baxter International Inc. Models of thrombotic thrombocytopenic purpura and methods of use thereof
ES2685503T3 (es) * 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
HUE028688T2 (en) * 2009-09-21 2017-01-30 Baxalta GmbH Stabilized liquid and lyophilized adamts13 formulations
CA2805557A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
CA2757585C (en) * 2010-11-17 2022-07-19 Puget Sound Blood Center Enhanced cleavage of von willebrand factor by adamts13

Also Published As

Publication number Publication date
EP3388529A1 (en) 2018-10-17
US20140154709A1 (en) 2014-06-05
AU2009322367B2 (en) 2015-03-26
JP2020022515A (ja) 2020-02-13
KR20110104940A (ko) 2011-09-23
US10209263B2 (en) 2019-02-19
JP2017153490A (ja) 2017-09-07
KR101670103B1 (ko) 2016-10-27
US8415114B2 (en) 2013-04-09
US20100143957A1 (en) 2010-06-10
US8623612B2 (en) 2014-01-07
US9488651B2 (en) 2016-11-08
CA2745805C (en) 2021-01-19
PL2358895T3 (pl) 2019-03-29
US20190145989A1 (en) 2019-05-16
US9110085B2 (en) 2015-08-18
US20160033506A1 (en) 2016-02-04
JP6111016B2 (ja) 2017-04-05
US20130252263A1 (en) 2013-09-26
JP6691893B2 (ja) 2020-05-13
CA2745805A1 (en) 2010-06-10
US20170153255A1 (en) 2017-06-01
JP2015213513A (ja) 2015-12-03
US10900979B2 (en) 2021-01-26
EP2358895A1 (en) 2011-08-24
WO2010065742A1 (en) 2010-06-10
AU2009322367A1 (en) 2011-06-30
JP2012510817A (ja) 2012-05-17
CA3098952A1 (en) 2010-06-10
EP2358895B1 (en) 2018-05-30
EP3388529A8 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
ES2685503T3 (es) Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
Ghorbani et al. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
CL2017000546A1 (es) Análisis de coagulación universal microfluídico basado en chips
ES2618506T3 (es) Marcador epigenético para la identificación de linfocitos T CD3CD4 positivos
BRPI1005655A2 (pt) Sistemas, dispositivos e métodos para medição do hematócrito de sangue integral com base na velocidade de preenchimento inicial
BR112012008682A2 (pt) "dispositivo de depleção de oxigênio, e, método para remover oxigênio de células vermelhas do sangue."
CR20120326A (es) Dispositivo portátil de monitorización de la coagulación y método de evaluación de la respuesta de coagulación
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
CR20110211A (es) Método de procesamiento de electrodos para conducir a la estimulación
UY30893A1 (es) Metodos y dispositivos para el diagnostico de apendicitis
Draenert et al. The prevalence of tooth hypersensitivity following periodontal therapy with special reference to root scaling. A systematic review of the literature.
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
CL2008003282A1 (es) Poblacion de celulas humanas que expresan cd34 las cuales son obtenidas a partir de expansion de celulas de sangre de cordon umbilical en presencia de celulas menstruales humanas, metodo para obtener dichas celulas.
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
BR112014015424A2 (pt) detecção de células derivadas de tecido do cordão umbilical humano
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
ES2603616T3 (es) Aparato, método y medio de almacenamiento legible por ordenador para evaluar el estado fisiológico de un paciente
MX2023013438A (es) Métodos de diseño de hla y composiciones para el tratamiento de la autoinmunidad.
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
Peixoto et al. Bonding of adhesive luting agents to caries-affected dentin induced by a microcosm biofilm model
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
Tandon et al. Label-free multiphoton microscopy for the detection and monitoring of calcific aortic valve disease
ES2509567T3 (es) Identificación de variación genética en tejidos afectados